Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials
- 11 May 2011
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 79 (2), 219-228
- https://doi.org/10.1002/ccd.22996
Abstract
Objective: To compare the geometrical parameters of a bioresorbable vascular scaffold (BVS) with a standard metallic stent. Background: The introduction of polymeric bioresorbable materials in the design of novel coronary scaffolds may affect some geometrical parameters, such as eccentricity and symmetry indices, previously introduced as IVUS criteria for optimal metallic stent deployment. Methods: From ABSORB Cohort A, ABSORB Cohort B, SPIRIT I, and SPIRIT II, all patients implanted with BVS 1.0, BVS 1.1, or XIENCE V, respectively and intravascular ultrasound analyses post‐implantation were selected. The eccentricity index was calculated frame by frame and expressed as an average per device (minimum diameter/maximum diameter). The symmetry index of the device was reported as ([maximum diameter − minimum diameter]/maximum diameter).Six months major adverse cardiac events (MACE) were analyzed. Results: A total of 242 patients were selected (BVS 1.0: n = 28, BVS 1.1: n = 94, XIENCE V: n = 120). The BVS exhibited a significantly lower eccentricity index (BVS 1.0: 0.83 ± 0.09; BVS 1.1: 0.85 ± 0.08; XIENCE V: 0.90 ± 0.06; P < 0.01) and a significantly higher symmetry index (BVS 1.0: 0.30 ± 0.07; BVS 1.1: 0.31 ± 0.06, XIENCE V 0.26 ± 0.07; P < 0.01) as compared to the XIENCE V. An inverse correlation was found between the symmetry and eccentricity indices for both (BVS r = −0.69, P < 0.01; XIENCE V r = −0.61, P < 0.01). No differences in MACE were detected between the groups according to their geometrical parameters. Conclusions: The introduction of a new polymeric material in the design of BVS resulted in a lower eccentricity index and a higher symmetry index as compared to metallic stents, without detectable impact in MACE, at 6 months.Keywords
This publication has 29 references indexed in Scilit:
- Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery StenosisCirculation, 2010
- Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence TomographyJACC: Cardiovascular Interventions, 2009
- A comparison of the mechanical performance characteristics of seven drug‐eluting stent systemsCatheterization and Cardiovascular Interventions, 2009
- The Virtual Histology Intravascular Ultrasound Appearance of Newly Placed Drug-Eluting StentsThe American Journal of Cardiology, 2008
- Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trialsCatheterization and Cardiovascular Interventions, 2007
- Revisiting late loss and neointimal volumetric measurements in a drug‐eluting stent trial: Analysis from the SPIRIT FIRST trialCatheterization and Cardiovascular Interventions, 2006
- Findings of intravascular ultrasound during acute stent thrombosisHeart, 2004
- Assessment of the trackability, flexibility, and conformability of coronary stents: A comparative analysisCatheterization and Cardiovascular Interventions, 2003
- Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stentsJournal of the American College of Cardiology, 1994